Covid-19 vaccine supply chains and the Defense Production Act

Chad Bown

Oxford Review of Economic Policy, 2022, vol. 38, issue 4, 771-796

Abstract: In response to the Covid-19 pandemic, the US government used novel policies to accelerate research, development, and production of a diversified portfolio of new vaccines. This article begins by describing the Defense Production Act (DPA) of 1950 and the initial ‘priority-rated’ contracts agreed to under Operation Warp Speed in 2020 to expedite manufacturing and achieve scale, which succeeded in producing hundreds of millions of doses of Covid-19 vaccines by early 2021. However, a puzzle soon emerged, as the scale of US vaccine production was shortly thereafter overtaken by plants in the European Union and India. The paper investigates the trade-offs US policy-makers faced in early 2021—once much of the initial uncertainty about the safety and effectiveness of many Covid-19 vaccines had been resolved—about whether to recalibrate contracts to expand production capacity to help meet global, instead of US, vaccine demand. It also examines the emergence of input shortages and assesses whether both the price constraints implicit in the 2020 DPA contracts and business decisions made to quicken the process of bringing new vaccine plants online globally inadvertently exacerbated them. It also explores the potential need for complementary, input capacity-enhancing policies in the face of highly fragmented, cross-border Covid-19 vaccine supply chains.

Keywords: Covid-19 vaccines; advance market commitments; manufacturing; input shortages; Defense Production Act; priority-rated contracts (search for similar items in EconPapers)
Date: 2022
References: Add references at CitEc
Citations: View citations in EconPapers (4)

Downloads: (external link)
http://hdl.handle.net/10.1093/oxrep/grac026 (application/pdf)
Access to full text is restricted to subscribers.

Related works:
Working Paper: COVID-19 vaccine supply chains and the Defense Production Act (2022)
Working Paper: COVID-19 vaccine supply chains and the Defense Production Act (2022)
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:oup:oxford:v:38:y:2022:i:4:p:771-796.

Access Statistics for this article

Oxford Review of Economic Policy is currently edited by Christopher Adam

More articles in Oxford Review of Economic Policy from Oxford University Press and Oxford Review of Economic Policy Limited
Bibliographic data for series maintained by Oxford University Press ().